Drugs / Meningococcal B Recombinant vaccine
last change Feb 2018 re-read 2 minutes ago

Meningococcal B Recombinant vaccine

Vaccine

Developed for
meningococcal infection
Investigated by
GlaxoSmithKline

Trials 1 · a red edge is where a trial was stopped

2017201820192020202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT02946385 Nov 2016 → Feb 2018 meningococcal infection GlaxoSmithKline Completed No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as Meningococcal B Recombinant vaccine ClinicalTrials.gov intervention name — accepted as the source's own label NCT02946385
Modality Vaccine “Meningococcal B Recombinant vaccineNCT02946385